Dolutegravir Use at Conception - Additional Surveillance Data from Botswana

doi:10.1056/NEJMc1908155

. 2019 Aug 29;381(9):885-887.

doi: 10.1056/NEJMc1908155. Epub 2019 Jul 22.

Dolutegravir Use at Conception - Additional Surveillance Data from Botswana

Mmakgomo M Raesima¹, Chibuike M Ogbuabo², Vasavi Thomas³, Sara E Forhan⁴, Gadzikanani Gokatweng², Eldah Dintwa¹, Chipo Petlo¹, Catherine Motswere-Chirwa⁵, Elizabeth M Rabold⁴, Sarah C Tinker⁴, Shifawu Odunsi⁶, Sifelani Malima¹, Omphemetse Mmunyane¹, Thusoetsile Modise¹, Kelame Kefitlhile¹, Kunle Dare⁵, Mpho Letebele⁵, Michelle E Roland⁵, Cynthia A Moore⁴, Surbhi Modi⁴, Dhelia M Williamson⁴

Affiliations

¹ Botswana Ministry of Health and Wellness, Gaborone, Botswana.
² Botswana-University of Maryland School of Medicine Health Initiative, Gaborone, Botswana.
³ Centers for Disease Control and Prevention, Gaborone, Botswana cqi6@cdc.gov.
⁴ Centers for Disease Control and Prevention, Atlanta, GA.
⁵ Centers for Disease Control and Prevention, Gaborone, Botswana.
⁶ Peace Corps, Gaborone, Botswana.

PMID: 31329378
PMCID: PMC6713595
DOI: 10.1056/NEJMc1908155

Dolutegravir Use at Conception - Additional Surveillance Data from Botswana

Mmakgomo M Raesima et al. N Engl J Med. 2019.

. 2019 Aug 29;381(9):885-887.

doi: 10.1056/NEJMc1908155. Epub 2019 Jul 22.

Authors

Affiliations

¹ Botswana Ministry of Health and Wellness, Gaborone, Botswana.
² Botswana-University of Maryland School of Medicine Health Initiative, Gaborone, Botswana.
³ Centers for Disease Control and Prevention, Gaborone, Botswana cqi6@cdc.gov.
⁴ Centers for Disease Control and Prevention, Atlanta, GA.
⁵ Centers for Disease Control and Prevention, Gaborone, Botswana.
⁶ Peace Corps, Gaborone, Botswana.

PMID: 31329378
PMCID: PMC6713595
DOI: 10.1056/NEJMc1908155

No abstract available

PubMed Disclaimer

Comment in

Global HIV Treatment - Turning Headwinds to Tailwinds.
Havlir DV, Doherty MC. Havlir DV, et al. N Engl J Med. 2019 Aug 29;381(9):873-874. doi: 10.1056/NEJMe1909363. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339675 No abstract available.

Cited by

Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®.
Saint-Lary L, Lacroix I, Leroy V, Sommet A. Saint-Lary L, et al. Pharmacol Res Perspect. 2024 Aug;12(4):e1247. doi: 10.1002/prp2.1247. Pharmacol Res Perspect. 2024. PMID: 39086081 Free PMC article.
Metabolic implications and safety of dolutegravir use in pregnancy.
Dontsova V, Mohan H, Blanco C, Jao J, Greene NDE, Copp AJ, Zash R, Serghides L. Dontsova V, et al. Lancet HIV. 2023 Sep;10(9):e606-e616. doi: 10.1016/S2352-3018(23)00141-8. Epub 2023 Aug 4. Lancet HIV. 2023. PMID: 37549681 Free PMC article. Review.
The burden, prevention and care of infants and children with congenital anomalies in sub-Saharan Africa: A scoping review.
Leke AZ, Malherbe H, Kalk E, Mehta U, Kisa P, Botto LD, Ayede I, Fairlie L, Maboh NM, Orioli I, Zash R, Kusolo R, Mumpe-Mwanja D, Serujogi R, Bongomin B, Osoro C, Dah C, Sentumbwe-Mugisha O, Shabani HK, Musoke P, Dolk H, Barlow-Mosha L. Leke AZ, et al. PLOS Glob Public Health. 2023 Jun 28;3(6):e0001850. doi: 10.1371/journal.pgph.0001850. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37379291 Free PMC article.
The End Is in Sight: Current Strategies for the Elimination of HIV Vertical Transmission.
Yang L, Cambou MC, Nielsen-Saines K. Yang L, et al. Curr HIV/AIDS Rep. 2023 Jun;20(3):121-130. doi: 10.1007/s11904-023-00655-z. Epub 2023 Mar 27. Curr HIV/AIDS Rep. 2023. PMID: 36971951 Free PMC article. Review.
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.
Ngoufack Jagni Semengue E, Santoro MM, Ndze VN, Ka'e AC, Yagai B, Nka AD, Dambaya B, Takou D, Teto G, Fabeni L, Colizzi V, Perno CF, Ceccherini-Silberstein F, Fokam J. Ngoufack Jagni Semengue E, et al. PLOS Glob Public Health. 2022 Oct 11;2(10):e0000826. doi: 10.1371/journal.pgph.0000826. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962573 Free PMC article.

See all "Cited by" articles

References

1. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018;379:979–81. - PMC - PubMed
1. Daly L Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med 1992;22: 351–61. - PubMed
1. Tandberg D Improved confidence intervals for the difference between two proportions and number needed to treat (NNT), version 1. Albuquerque: University of New Mexico School of Medicine (https://www.cebm.net/wp-content/uploads/2014/04/Diff2PropCI49.xls).
1. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. DOI: 10.1056/NEJMoal905230 - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018;379:979–81. - PMC - PubMed

[2] Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018;379:979–81. - PMC - PubMed

[3] Daly L Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med 1992;22: 351–61. - PubMed

[4] Daly L Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med 1992;22: 351–61. - PubMed

[5] Tandberg D Improved confidence intervals for the difference between two proportions and number needed to treat (NNT), version 1. Albuquerque: University of New Mexico School of Medicine (https://www.cebm.net/wp-content/uploads/2014/04/Diff2PropCI49.xls).

[6] Tandberg D Improved confidence intervals for the difference between two proportions and number needed to treat (NNT), version 1. Albuquerque: University of New Mexico School of Medicine (https://www.cebm.net/wp-content/uploads/2014/04/Diff2PropCI49.xls).

[7] Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. DOI: 10.1056/NEJMoal905230 - DOI - PMC - PubMed

[8] Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. DOI: 10.1056/NEJMoal905230 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Dolutegravir Use at Conception - Additional Surveillance Data from Botswana

Affiliations

Dolutegravir Use at Conception - Additional Surveillance Data from Botswana

Authors

Affiliations

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical